Marissa Leonce

Marissa Leonce represents clients in mergers, acquisitions and other transactions. She also advises clients on shareholder activism defense, corporate governance and other general corporate matters.

• Alcon in its $753 million acquisition of Aerie Pharmaceuticals;
• Antares Pharma in its sale to Halozyme for $1 billion;
• Dicerna Pharmaceuticals in its sale to Novo Nordisk for $3.3 billion;
• MorphoSys in its $1.7 billion acquisition of Constellation Pharmaceuticals and its related financing from Royalty Pharma totaling over $2 billion;
• WeWork in its merger with BowX Acquisition Corp., a special purpose acquisition company, as a result of which WeWork would become a public company with an implied initial enterprise value of $9 billion;
• Boston Dynamics in its sale to Hyundai Motor Group for $1.1 billion;
• CerSci Therapeutics in its sale to ACADIA Pharmaceuticals for up to $939.5 million;
• Stemline Therapeutics in its sale to Menarini Group for up to $677 million;
• ArQule in its sale to Merck for $2.7 billion;
• Alder in its sale to Lundbeck for up to $1.95 billion;
• Clementia Pharmaceuticals in its sale to Ipsen for up to $1.31 billion;
• Carbonite in its $618.5 million acquisition of Webroot;
• United Natural Foods in its acquisition of SUPERVALU for $2.9 billion, including assumption of outstanding debt and liabilities;
• Hasbro in its $522 million acquisition of Saban Brands’ Power Rangers and other entertainment assets;
• Ultragenyx Pharmaceutical in its successful topping bid for Dimension Therapeutics;
• Merrimack Pharmaceuticals in its asset sale to Ipsen for up to $1.025 billion; and
• Intralinks Holdings, Inc., a leading global technology provider of secure enterprise content collaboration solutions, in its $820 million acquisition by Synchronoss Technologies, Inc.